Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Cilostazol with Aspirin in Minor Stroke or TIA
NCT06591390Phase 3Recruiting
- Sponsor
- Kafrelsheikh University
- Start
- Feb 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in ischemic stroke and Transient Ischemic Attack (TIA) comparing Ticagrelor + Aspirin with Cilostazol + Aspirin (2 arms). Primary endpoints: Rate of new stroke at 90 days and Rate of drug-related hemorrhagic complications at 90 days. Started Feb 2022; status: recruiting.
02
Drugs
ticagrelorcilostazol
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06591390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06591390.